H eart failure with a preserved left ventricular (LV) ejection fraction (HF-preserved EF) has been recognized as a clinical entity distinct from other forms of heart failure and defined predominantly by symptoms of dyspnea and fluid retention in the absence of a significant reduction in LV systolic function. 1, 2 Previous studies have indicated that HF-preserved EF accounts for a significant proportion of patients hospitalized with acute decompensated heart failure. 3, 4 However, the pathogenesis of HF-preserved EF remains less clear, 5, 6 and specific therapies targeting this population have failed to demonstrate meaningful improvements in clinical outcomes. [7] [8] [9] Therefore, guideline recommendations have focused on the treatment of sequelae of acute episodes of HF-preserved EF and the management of comorbidities. 2, 10, 11 
Clinical Perspective on p 75
Existing data on patients hospitalized with HF-preserved EF have been limited to single-center experiences or are from outdated series. [12] [13] [14] There are limited data on trends in the prevalence, treatment, and short-term outcomes of patients hospitalized with HF-preserved EF from around the United States. The present study sought to provide these data among patients hospitalized with HF-preserved EF (EF Ն50%) relative to those HF patients with borderline EF (40%ՅEFϽ50% [HF-borderline EF]) and those with reduced EF (EF Ͻ40% [HF-reduced EF]) and to describe recent trends in prevalence and outcomes.
Methods
The present study used the American Heart Association's Get With the Guidelines (GWTG) initiative, which has been described previously. 15 Briefly, this cardiovascular quality improvement program includes hospitals from across the United States and uses a pointof-service, interactive data collection tool. Outcome Sciences, Inc (Cambridge, MA) serves as the data collection and coordination center, and the Duke Clinical Research Institute serves as the data analysis center. Participation by each institution is voluntary. The heart failure component of GWTG (GWTG-HF) includes patients hospitalized for acute, decompensated heart failure based on the treating physician's clinical diagnosis. Over the period of the study, consecutive patients presenting to participating hospitals with new or worsening heart failure and those who developed significant symptoms of heart failure in the hospital (ie, heart failure was a discharge diagnosis) were enrolled in the registry. Patients were eligible regardless of LV function, and they were identified by hospital teams using methods similar to those of the Joint Commission. The present study included all patients entered in GWTG-HF between January 2005 and October 2010 who had EF measured and documented either before or during the index hospitalization.
The patient population was subsequently stratified by EF Ͻ40% (HF-reduced EF), 40%ՅEFϽ50% (HF-borderline EF), and EF Ն50% (HF-preserved EF). Hospital characteristics, patient demographics, medical history, admission data (including vital signs and laboratory studies), in-hospital events, procedures, and discharge data (including disposition and performance measures) were compared among our strata. Temporal trends in the diagnosis of heart failure by EF, as well as therapies and outcomes, were also assessed by year. Rates of medication use included all study patients, regardless of contraindication or intolerance, both in hospital and at discharge. Multivariable analyses were performed to control for baseline characteristics before quality measures and clinical outcomes across EF were compared.
Quality measures applicable to heart failure patients regardless of EF at discharge were assessed, including anticoagulation for atrial fibrillation (AF), smoking cessation, blood pressure control, discharge instructions, and lipid-lowering therapy in patients with documented atherosclerosis or diabetes mellitus. In-hospital procedures were also analyzed. Clinical outcomes studied included hospital length of stay, in-hospital mortality, and disposition (home, hospice, rehabilitation, skilled nursing facility, or acute care).
Data collected through the GWTG-HF program are used primarily for quality-improvement purposes at each individual site, and the data are collected anonymously without any patient identifiers. Therefore, informed consent was waived under the common rule. However, all participating sites were required to comply with local regulatory and privacy policies. Institutional review board approval was granted to the Duke Clinical Research Institute to analyze aggregate deidentified data for research purposes.
Study Population
A total of 127 252 patients were admitted for heart failure to 281 hospitals fully participating in the GWTG-HF program from 2005 to 2010. We excluded 16 631 patients and 6 sites for lack of quantitative EF data, over half of whom had qualitative assessment of EF (nϭ9347). This yielded a final study population of 110 621 patients from 275 hospitals. Patients with quantified EF (nϭ110 621) included in the study were compared with those for whom EF was missing or not quantified (nϭ16 631) and who thus were excluded from the study population to assess representativeness. Although many characteristics were similar, some notable differences were found (see Table I in the online-only Data Supplement).
Statistical Methods
Continuous variables are presented as medians with interquartile ranges, and categorical variables are expressed as percentages. To test for associations between EF groups, patient and hospital characteristics, and outcomes, the Kruskal-Wallis test was used for continuous variables and the Pearson 2 test was used for categorical variables. For the analyses of temporal trends in quality of care and clinical outcomes, P values are based on 2 rank-based group means score statistics for all categorical row variables in univariate analyses.
A multivariable logistic regression model was fitted to further examine the effect of EF on the quality measures and other outcomes. HF-reduced EF was considered the reference group. The effect of HF-borderline EF and HF-preserved EF versus the reference group on outcomes was estimated. The generalized estimating equation method with exchangeable working correlation structure was used to account for within-hospital clustering. The method produces estimates similar to those from ordinary logistic regression, but the estimated variances of the estimates are adjusted for the correlation of outcomes within each hospital. A standard list of variables was entered into a multivariable model, including patient characteristics of age, sex, race, insurance, history of AF, atrial flutter, chronic obstructive pulmonary disease or asthma, diabetes mellitus, hyperlipidemia, hypertension, peripheral vascular disease, prior myocardial infarction, cerebrovascular accident or transient ischemic attack, prior heart failure, anemia, renal insufficiency, smoking, and ischemic history, as well as the site characteristics of hospital size, hospital type, and region. This standard list of variables for GWTG analyses was derived from several previous studies using the same data set. Variables that had Ͼ5% proportion of missing data were excluded. Odds ratios (ORs) and 95% confidence intervals are presented. Tests for interaction between EF and major covariates were conducted. A value of PϽ0.05 was considered significant for all tests. Multivariable logistic regression models with the generalized estimating equation method were developed to test how the outcomes changed on a continuous basis and reported as change per 1 year for each EF group. For the analysis of trends over time, calendar time was treated as a continuous variable in the time trend model, with calendar quarter used as a covariate and the increase over each 4 quarters (calendar years) reported. Covariates used in this adjustment were from the same standard list except for insurance and hospital type (all hospital factors missing were excluded from the models).
All statistical analyses of the aggregate, deidentified data were performed by the Duke Clinical Research Institute using SAS software (version 9.2; SAS Institute, Cary, NC). All investigators had direct access to the primary data and take full responsibility for the analyses presented here.
Results
Among 110 621 patients admitted with heart failure from January 2005 to December 2010, 50% (55 083) had HFreduced EF, 14% (15 184) had HF-borderline EF, and 36% (40 354) had HF-preserved EF. Baseline demographics, vital signs, medical history, and laboratory studies on admission are shown in Table 1 . Patients with HF-preserved EF were older, more likely to be female, and more likely to have a history of hypertension, AF, and kidney disease compared with patients with HF-reduced EF. On admission, both average systolic blood pressure and body mass index were higher in the HF-preserved EF group, and that group had lower levels of B-type natriuretic peptide (BNP), N-terminal pro-BNP, and troponin on admission. Among participating hospitals, the average hospital size was Ϸ420 beds, with 52% of patients admitted to hospitals employing residents and 58% admitted to hospitals classified as academic centers. Sixty-nine percent of patients were admitted to a hospital capable of performing percutaneous coronary interventions, 72% to a hospital with cardiac surgery capability, and 10% to cardiac transplant centers. All census regions of the United States were represented. Patients with HF-preserved EF were more likely to be hospitalized without undergoing any procedure (84%) compared with patients with HF-reduced EF (69%) or HFborderline EF (80%; PϽ0.0001). Rates of each individual procedure were lower in the HF-preserved EF group except for dialysis or ultrafiltration (4.8% for HF-preserved EF versus 4.6% and 3.1% for HF-borderline EF and HFreduced EF, respectively; PϽ0.001). Even after adjustment for patient and hospital characteristics, patients with HFborderline EF and HF-preserved EF were less likely to undergo any procedure, right heart catheterization, and left heart catheterization compared with patients with HF-reduced EF (see Table II in the online-only Data Supplement).
The unadjusted rates of use of medications proven to improve outcomes in patients with HF-reduced EF (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, ␤-blockers, and aldosterone antagonists) were significantly lower in those with HF-preserved EF or HFborderline EF (see Table 2 ). Quality measures broadly applicable across cardiovascular patients such as anticoagulation for AF, blood pressure control, and lipid-lowering therapy were also less likely to be achieved in patients with HF-preserved EF compared with those with HF-borderline EF or HF-reduced EF.
In univariate analyses, patients with HF-preserved EF had significantly higher systolic blood pressure at discharge (128 mm Hg) compared with patients with HF-borderline EF (124 mm Hg) or HF-reduced EF (116 mm Hg; PϽ0.0001 for 3-way comparison). A small but significant difference in length of stay was observed; more patients with HF-preserved EF were hospitalized for Ͼ4 days (48% for HFpreserved EF versus 47% for HF-borderline EF and 45% for HF-reduced EF; PϽ0.001). They were also less likely to be discharged home, in favor of inpatient rehabilitation or a skilled nursing facility, and had an intermediate rate of in-hospital mortality (2.5% versus 2.3% for HF-borderline EF and 2.7% for HF-reduced EF; PϽ0.001 for the unadjusted comparison across discharge status).
After adjustment for common confounders, patients in each EF category received guideline-recommended therapies to a similar degree with respect to anticoagulation for AF, smoking cessation, and lipid-lowering therapy (see Table 3 ). However, blood pressure at discharge was still significantly less likely to be controlled in patients with HF-preserved EF and HF-borderline EF compared with HF-reduced EF (adjusted OR, 0.53 for HF-borderline EF versus HF-reduced EF and 0.44 for HF-preserved EF versus HF-reduced EF; PϽ0.001 for each). Patients with HF-preserved EF were also In analyses of temporal trends, the proportion of patients hospitalized with HF-preserved EF increased from 33% in 2005 to 39% in 2010 (see Figure 1 ) with a concomitant decrease in the proportion with HF-reduced EF from 52% to 47% and stable rates of HF-borderline EF at Ϸ15% (PϽ0.0001 for overall trend, unadjusted). Rates of angioten- EF indicates ejection fraction; OR, odds ratio; CI, confidence interval; and ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Multivariable analysis of overall quality measures and outcomes. The group with EF Ͻ40% (heart failure-reduced EF) was used as the reference group for all comparisons. Adjusted for age, sex, race, insurance, history of atrial fibrillation, atrial flutter, chronic obstructive pulmonary disease or asthma, diabetes mellitus, hyperlipidemia, hypertension, peripheral vascular disease, prior myocardial infarction, cerebrovascular accident/transient ischemic attack, prior heart failure, anemia, renal insufficiency, smoking, ischemic history, hospital size, hospital type, and region.
*Excludes patients transferred to other acute care facilities. †Testing for interaction between EF and age was significant (Pϭ0.03) for the end point of in-hospital mortality. Table 4 ). Temporal trends in renal function are shown in Table III in the online-only Data Supplement. For each year during the study period, quality-of-care measures applicable across groups of EF showed a trend toward improvement. In univariate analyses, patients in all EF groups were more likely to receive discharge instructions, smoking cessation counseling, anticoagulation for AF, and lipid-lowering therapy and to achieve goal blood pressure at discharge over the 5 years (see Figure 2 ). These improvements were persistently significant in the multivariable generalized estimating equation model across EF groups, with the exception of blood pressure control (see Table 4 ). In multivariable analysis, there was no significant improvement in the achievement of goal blood pressure goal at discharge in any EF group over the study period (adjusted OR, 1.0 per year for each group; Pϭ0.40, Pϭ0.64, and Pϭ0.41 for HFreduced EF, HF-borderline EF, and HF-preserved EF, respectively).
Unadjusted rates of in-hospital mortality for patients with HF-preserved EF decreased from 3.32% in 2005 to 2.35% in 2010 (Pϭ0.015) but were stable for patients with HFreduced EF (3.03%-2.83%; Pϭ0.522) and HF-borderline EF (2.69%-2.88%; Pϭ0.320; see Figure 3 ). There were no clinically significant changes in discharge status (home versus skilled nursing facility) over the study period for any EF group in both unadjusted and adjusted analyses. However, there was a significant improvement in risk-adjusted in- 
Discussion
In this cohort of Ͼ110 000 hospitalizations for heart failure, HF-preserved EF accounted for more than one third of all hospitalizations, and these patients represented an increasing share of heart failure hospitalizations over the study period. There was significant improvement in several quality measures in patients with HF-preserved EF during the study period except for blood pressure control at discharge. After risk adjustment, patients with HF-preserved EF had intermediate rates of in-hospital mortality and were the only group observed to have a decline in in-hospital mortality rates during the study period.
The rise in the prevalence of HF-preserved EF relative to HF-reduced EF emphasizes the growing need for effective, evidence-based therapies in this population. Although such an increase may represent heightened physician recognition of HF-preserved EF as a disease process, other studies have demonstrated similar rates of HF-preserved EF among patients hospitalized for heart failure. 3, 4 Among those hospitalized with heart failure, HF-preserved EF is rising rapidly and could easily eclipse HF-reduced EF as the predominant disease manifestation over the next decade. Furthermore, care of these patients is likely to become more complicated. Patients with HF-preserved EF in our study were significantly older, more likely to be female, and more likely to have hypertension, renal disease, AF, and pulmonary disease than those with HF-reduced EF or HF-borderline EF. These characteristics are consistent with populations reported in both the Acute Decompensated Heart Failure National Registry (ADHERE) and Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) registries, 3, 4 as well as older, regional studies. 13, 14, 16 As observed in this study, there were significant differences in in-hospital therapies across EF categories. Patients with HF-preserved EF were less likely to receive therapies broadly recommended to reduce cardiovascular risk (eg, optimal blood pressure control) and less likely to undergo EF indicates ejection fraction; OR, odds ratio; CI, confidence interval; and ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Unadjusted and multivariable adjusted time trends of quality measures and outcomes were based on the generalized estimating equation. ORs presented are per 1-year increase from 2005 to 2010. Multivariable results are adjusted for EF, calendar year, age, sex, race, insurance, history of atrial fibrillation, atrial flutter, chronic obstructive pulmonary disease or asthma, diabetes mellitus, hyperlipidemia, hypertension, peripheral vascular disease, prior myocardial infarction, cerebrovascular accident/transient ischemic attack, prior heart failure, anemia, renal insufficiency, smoking, ischemic history, hospital size, hospital type, and region.
*Excludes patients transferred to other acute care facilities.
in-hospital procedures. Although increased comorbidities in patients with HF-preserved EF and the absence of specific recommendations targeting this population certainly can account for some of these disparities, it is clear that more clinical trials and evidence are needed to direct the management of HF-preserved EF. Current therapies proven to be beneficial in HF-reduced EF either have failed to improve outcomes in HF-preserved EF (angiotensin receptor blockers 8, 9 ) or have yet to be rigorously studied (␤-blockers). The ongoing Trial for Heart Failure Patients With Preserved Systolic Function (TOPCAT) study will likely provide valuable data on the utility of aldosterone antagonism in this population. 17 During the study period, we observed a decrease in the prescription of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers at discharge and an increase in ␤-blocker use across EF groups. This may be partly the result of the failure of contemporary trials to demonstrate a clinical advantage for the use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker in HF-preserved EF. 8, 9 However, these findings may also represent an increasing prevalence of contraindications and comorbidities precluding the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ie, renal dysfunction), particularly within the growing HF-preserved EF population (in which we observed a higher rate of renal disease). Because quality measures related to such medications are currently applicable only to patients with LV systolic dysfunction, such contraindications and intolerances were not applied in the present study. In the overall cohort, there were also improvements in broadly applicable cardiovascular therapies such as blood pressure control, anticoagulation for AF, lipid-lowering therapy, and smoking cessation, which have been demonstrated to benefit patients with cardiovascular disease regardless of EF.
Although elevated blood pressure is well known to contribute to both poor cardiovascular outcomes and LV hypertrophy and subsequent diastolic dysfunction, 10 patients with HF-preserved EF were less likely to be discharged with blood pressure at goal. In fact, after risk adjustment, blood pressure control at discharge was the only metric that failed to improve over the study period. Although this may signify that blood pressure is more difficult to control in patients with HF-preserved EF than in those with significantly impaired systolic function, there nonetheless remains opportunity for improvement in the current care of these patients.
Discrepancies in the implementation of broadly applicable therapies also may be due to treatment biases in which physicians perceive patients with HF-preserved EF to be less sick than their counterparts with low EF. This is supported by the fact that patients with HF-preserved EF were less likely 
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to receive heart failure discharge instructions, even after adjustment in multivariable analysis. Previous descriptions of "diastolic" heart failure asserted that mortality was lower in this population. 18 Yet, this assumption may be incorrect. Our data demonstrate relatively small differences in absolute in-hospital mortality rates across EF strata (2.5% for HFpreserved EF, 2.3% for HF-borderline EF, and 2.7% for HF-reduced EF). Furthermore, patients with HF-preserved EF in our cohort had a significantly longer hospital stay and were much more likely to require skilled nursing care, even after multivariable adjustment for confounders. These observations confirm data from OPTIMIZE-HF 3 and from a study by Senni et al 19 that reviewed several epidemiological studies of heart failure outcomes. Their data suggest that outcomes in patients with a clinical diagnosis of heart failure are not substantially different across the spectrum of EF. However, the overall absolute rate of in-hospital mortality for patients with HF-preserved EF in the present study (2.5%) differed from those previously reported in the OPTIMIZE-HF (2.9%) and ADHERE (2.8%) cohorts. 3, 4 Several explanations for this discrepancy are likely. One may be that the ADHERE and OPTIMIZE-HF studies involved earlier time frames than the present study. In-hospital mortality from the present study in 2006 matches that of the OPTIMIZE-HF cohort published that same year (2.8%). There were also differences in the portion of patients in whom EF was quantified. In the OPTIMIZE-HF population, patients without quantitative EF measurements were included in the HF-preserved EF group (if a qualitative EF assessment did not show moderate/severe LV dysfunction). 3 Other differences in the patient populations and their treatment also may account for these modest differences in inhospital mortality.
Despite these findings, patients with HF-preserved EF in our study were the only group in whom improvement in short-term mortality was observed over the 5-year study. A single source for such a decline is difficult to identify. One possibility is that more patients were receiving a HFpreserved EF diagnosis over time and that these patients have less severe disease and were at lower risk for in-hospital mortality. Significant differences in BNP levels or in the proportion with BNP Ͻ100 pg/dL were not observed, however. Another possibility is that patients with HF-preserved EF represent Ͼ1 disease process, which could not be adjusted for in multivariable analysis. 20 A further possibility is advancements in the care of these patients. However, this is less likely given that the several trials of therapies in HFpreserved EF during this period did not precipitate dramatic paradigm shifts in care. 8, 9, 11, 21 A decline in the use of agents found to increase mortality in patients hospitalized for heart failure is possible. In a similar observational study run during the period immediately preceding ours, investigators in the ADHERE registry highlighted the declining use of inotropes in hospitalized patients with heart failure. They cite this as 1 potential contributor to a drop in mortality over the period of that study. 22 Additional data from ADHERE, which included patients with both HF-preserved EF and HF-reduced EF, emphasized the adverse effect of inotropes across all populations of heart failure. 23 The improvements in broad cardiovascular care that we observed spanned the spectrum of EF without a similar effect on mortality throughout. This raises the possibility of a more profound treatment effect of routine cardiovascular prevention therapies in patients with HFpreserved EF than in those with borderline or reduced EF. However, current data supporting this hypothesis are lacking.
Thus, the source of declining mortality in patients with HF-preserved EF is likely multifactorial and remains a hypothesis-generating finding in that it became significant only after multivariable adjustment. However, such a trend may signify improved recognition of the disease and attention to its comorbidities. In the absence of effective, targeted therapies, this remains the current standard of care in this population. 2, 10 
Limitations
The data presented here are derived from an observational registry in which participation is voluntary and targeted at sites motivated to improve quality. They are thus subject to the inherent limitations of such methods, including biases related to patient population, patient selection and reporting, and the self-selection of sites that agree to participate in GWTG-HF. Therefore, this patient population may not be representative of the United States as a whole. Furthermore, given the large sample size, many comparisons may result in statistically significant results of questionable clinical significance. The diagnosis of heart failure itself also may have been confounded in patients with HF-preserved EF. Although standard criteria have been proposed for the diagnosis of HF-preserved EF, they frequently rely on the assessment of diastolic dysfunction, which can be difficult to demonstrate noninvasively (and was not available in the present study). 1, 24 The diagnosis of HF-preserved EF in our cohort depended on the assessment of EF combined with the clinical presentation of heart failure (signs and/or symptoms of volume overload). However, the proportion of patients with BNP levels Ͻ100 pg/mL in each stratum of EF was Ϸ5%, comparable to prior reports of the false-negative rate for this test in patients with clinically diagnosed heart failure. 3, 25 Additionally, we must acknowledge the limitations inherent in using EF as a global assessment of myocardial health. Although it can provide an important visual assessment of LV contraction, EF captures only a fraction of data on hemodynamics, loading conditions, and diastolic function. Furthermore, EF in the present study could have been measured by a variety of different modalities (echocardiography, cardiac magnetic resonance, angiography, etc). Thus, there may be some heterogeneity in the study population owing both to diagnostic variability and to limitations in the assessment of EF. Finally, we cannot exclude residual measured and unmeasured confounding factors that may account for different outcomes among these groups. Although our model adjusted for such discrepancies, it is impossible to correct for such an effect entirely.
Conclusions
Among hospitalizations for heart failure, HF-preserved EF represents a growing proportion and may overtake HFreduced EF as the predominant form of acute heart failure.
Steinberg et al Heart Failure With Preserved EF Trends
Broadly applicable therapies for cardiovascular disease were increasingly implemented in all EF groups over the study period; however, there remains opportunity for improved blood pressure control in patients with HF-preserved EF. Although HF-preserved EF resulted in significant morbidity and mortality comparable to that of the entire cohort, it was the only group in our study in whom an improvement in risk-adjusted in-hospital mortality was observed over the study period. Additional studies are needed to confirm and to investigate this trend and to fill an important but unmet demand for evidence-based therapies and quality measures for patients with HF-preserved EF.
Sources of Funding
The GWTG-HF program is provided by the American Heart Association. GWTG-HF has been funded in the past through support from Medtronic, GlaxoSmithKline, . Using multivariable models, we examined trends in therapies and outcomes. There were 55% of patients with HF-reduced EF, 14% with HF-borderline EF, and 36% with HF-preserved EF. From 2005 to 2010, the proportion of hospitalizations for HF-preserved EF increased from 33% to 39% (PϽ0.0001). Although many heart failure quality metrics cannot be applied appropriately to the HF-preserved EF population, there are broadly applicable cardiovascular prevention goals such as blood pressure control and discharge instructions that are particularly important for patients with HF-preserved EF but less likely to be achieved. In-hospital mortality for patients with HF-preserved EF remains comparable to that for patients with HF-reduced EF. In-hospital mortality for HF-preserved EF decreased from 3.32% in 2005 to 2.35% in 2010 but was stable for patients with HF-reduced EF. Among hospitalizations for heart failure, HF-preserved EF represents a growing proportion and may overtake HF-reduced EF as the predominant form of acute heart failure. There remains an important opportunity for identification of evidence-based therapies in patients with HF-preserved EF. <0.001 Multivariable analysis of overall quality measures and outcomes. Group with EF <40% (HF-reduced EF) used as reference group for all comparisons. Adjusted for: age, gender, race, insurance, history of atrial fibrillation, atrial flutter, COPD or asthma, diabetes, hyperlipidemia, hypertension, PVD, prior MI, CVA/TIA, prior heart failure, anemia, renal insufficiency, smoking, ischemic history, body mass index, hemoglobin, serum creatinine, blood urea nitrogen, hospital size, hospital type, and region. *Excludes patients transferred out to other acute care facilities. EF: ejection fraction; OR: odds ratio; 95% CI: 95% confidence interval; ACEI/ARB: angiotensin converting enzyme inhibitor or angiotensin receptor blocker; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease; MI: myocardial infarction; CVA/TIA: cerebrovascular accident/transient ischemic attack. 
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Trends in Patients Hospitalized With Heart Failure and
H eart failure with a preserved left ventricular (LV) ejection fraction (HF-preserved EF) has been recognized as a clinical entity distinct from other forms of heart failure and defined predominantly by symptoms of dyspnea and fluid retention in the absence of a significant reduction in LV systolic function. 1,2 Previous studies have indicated that HF-preserved EF accounts for a significant proportion of patients hospitalized with acute decompensated heart failure. 3, 4 However, the pathogenesis of HF-preserved EF remains less clear, 5, 6 and specific therapies targeting this population have failed to demonstrate meaningful improvements in clinical outcomes. [7] [8] [9] Therefore, guideline recommendations have focused on the treatment of sequelae of acute episodes of HF-preserved EF and the management of comorbidities. 2, 10, 11 Clinical Perspective on p Existing data on patients hospitalized with HF-preserved EF have been limited to single-center experiences or are from outdated series. [12] [13] [14] There are limited data on trends in the prevalence, treatment, and short-term outcomes of patients hospitalized with HF-preserved EF from around the United States. The present study sought to provide these data among patients hospitalized with HF-preserved EF (EF �50%) relative to those HF patients with borderline EF (40%�EF�50% [HF-borderline EF]) and those with reduced EF (EF �40% [HF-reduced EF]) and to describe recent trends in prevalence and outcomes.
Methods
The patient population was subsequently stratified by EF �40% (HF-reduced EF), 40%�EF�50% (HF-borderline EF), and EF �50% (HF-preserved EF). Hospital characteristics, patient demographics, medical history, admission data (including vital signs and laboratory studies), in-hospital events, procedures, and discharge data (including disposition and performance measures) were compared among our strata. Temporal trends in the diagnosis of heart failure by EF, as well as therapies and outcomes, were also assessed by year. Rates of medication use included all study patients, regardless of contraindication or intolerance, both in hospital and at discharge. Multivariable analyses were performed to control for baseline characteristics before quality measures and clinical outcomes across EF were compared.
Study Population
A total of 127 252 patients were admitted for heart failure to 281 hospitals fully participating in the GWTG-HF program from 2005 to 2010. We excluded 16 631 patients and 6 sites for lack of quantitative EF data, over half of whom had qualitative assessment of EF (n�9347). This yielded a final study population of 110 621 patients from 275 hospitals. Patients with quantified EF (n�110 621) included in the study were compared with those for whom EF was missing or not quantified (n�16 631) and who thus were excluded from the study population to assess representativeness. Although many characteristics were similar, some notable differences were found (see Table I in the online-only Data Supplement).
Statistical Methods
Continuous variables are presented as medians with interquartile ranges, and categorical variables are expressed as percentages. To test for associations between EF groups, patient and hospital characteristics, and outcomes, the Kruskal-Wallis test was used for continuous variables and the Pearson � 2 test was used for categorical variables. For the analyses of temporal trends in quality of care and clinical outcomes, P values are based on � 2 rank-based group means score statistics for all categorical row variables in univariate analyses.
A multivariable logistic regression model was fitted to further examine the effect of EF on the quality measures and other outcomes. HF-reduced EF was considered the reference group. The effect of HF-borderline EF and HF-preserved EF versus the reference group on outcomes was estimated. The generalized estimating equation method with exchangeable working correlation structure was used to account for within-hospital clustering. The method produces estimates similar to those from ordinary logistic regression, but the estimated variances of the estimates are adjusted for the correlation of outcomes within each hospital. A standard list of variables was entered into a multivariable model, including patient characteristics of age, sex, race, insurance, history of AF, atrial flutter, chronic obstructive pulmonary disease or asthma, diabetes mellitus, hyperlipidemia, hypertension, peripheral vascular disease, prior myocardial infarction, cerebrovascular accident or transient ischemic attack, prior heart failure, anemia, renal insufficiency, smoking, and ischemic history, as well as the site characteristics of hospital size, hospital type, and region. This standard list of variables for GWTG analyses was derived from several previous studies using the same data set. Variables that had �5% proportion of missing data were excluded. Odds ratios (ORs) and 95% confidence intervals are presented. Tests for interaction between EF and major covariates were conducted. A value of P�0.05 was considered significant for all tests. Multivariable logistic regression models with the generalized estimating equation method were developed to test how the outcomes changed on a continuous basis and reported as change per 1 year for each EF group. For the analysis of trends over time, calendar time was treated as a continuous variable in the time trend model, with calendar quarter used as a covariate and the increase over each 4 quarters (calendar years) reported. Covariates used in this adjustment were from the same standard list except for insurance and hospital type (all hospital factors missing were excluded from the models).
Results
Among 110 621 patients admitted with heart failure from January 2005 to December 2010, 50% (55 083) had HFreduced EF, 14% (15 184) had HF-borderline EF, and 36% (40 354) had HF-preserved EF. Baseline demographics, vital signs, medical history, and laboratory studies on admission are shown in Table 1 . Patients with HF-preserved EF were older, more likely to be female, and more likely to have a history of hypertension, AF, and kidney disease compared with patients with HF-reduced EF. On admission, both average systolic blood pressure and body mass index were higher in the HF-preserved EF group, and that group had lower levels of B-type natriuretic peptide (BNP), N-terminal pro-BNP, and troponin on admission. Among participating hospitals, the average hospital size was �420 beds, with 52% of patients admitted to hospitals employing residents and 58% admitted to hospitals classified as academic centers. Sixty-nine percent of patients were admitted to a hospital EF indicates ejection fraction; BMI, body mass index; LVEF, left ventricular ejection fraction; ICD, implantable cardioverter-defibrillator; CRT-P, cardiac resynchronization therapy-pacemaker; CRT-D, cardiac resynchronization therapy-defibrillator; CAD, coronary artery disease; CVA/TIA, cerebrovascular accident/ transient ischemic attack; BNP, B-type natriuretic peptide; and NT-proBNP, N-terminal pro-BNP. Baseline characteristics, comorbidities, admission data, and laboratory studies are stratified by EF. Values are median (interquartile range) when appropriate.
*Chronic kidney disease defined as glomerular filtration rate �60 mL � min �1 � 1.73 m �2 or in-hospital dialysis.
capable of performing percutaneous coronary interventions, 72% to a hospital with cardiac surgery capability, and 10% to cardiac transplant centers. All census regions of the United States were represented. Patients with HF-preserved EF were more likely to be hospitalized without undergoing any procedure (84%) compared with patients with HF-reduced EF (69%) or HFborderline EF (80%; P�0.0001). Rates of each individual procedure were lower in the HF-preserved EF group except for dialysis or ultrafiltration (4.8% for HF-preserved EF versus 4.6% and 3.1% for HF-borderline EF and HFreduced EF, respectively; P�0.001). Even after adjustment for patient and hospital characteristics, patients with HFborderline EF and HF-preserved EF were less likely to undergo any procedure, right heart catheterization, and left heart catheterization compared with patients with HF-reduced EF (see Table II in the online-only Data Supplement).
The unadjusted rates of use of medications proven to improve outcomes in patients with HF-reduced EF (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, �-blockers, and aldosterone antagonists) were significantly lower in those with HF-preserved EF or HFborderline EF (see Table 2 ). Quality measures broadly applicable across cardiovascular patients such as anticoagulation for AF, blood pressure control, and lipid-lowering therapy were also less likely to be achieved in patients with HF-preserved EF compared with those with HF-borderline EF or HF-reduced EF.
In univariate analyses, patients with HF-preserved EF had significantly higher systolic blood pressure at discharge (128 mm Hg) compared with patients with HF-borderline EF (124 mm Hg) or HF-reduced EF (116 mm Hg; P�0.0001 for 3-way comparison). A small but significant difference in length of stay was observed; more patients with HF-preserved EF were hospitalized for �4 days (48% for HFpreserved EF versus 47% for HF-borderline EF and 45% for HF-reduced EF; P�0.001). They were also less likely to be discharged home, in favor of inpatient rehabilitation or a skilled nursing facility, and had an intermediate rate of in-hospital mortality (2.5% versus 2.3% for HF-borderline EF and 2.7% for HF-reduced EF; P�0.001 for the unadjusted comparison across discharge status).
After adjustment for common confounders, patients in each EF category received guideline-recommended therapies to a similar degree with respect to anticoagulation for AF, smoking cessation, and lipid-lowering therapy (see Table 3 ). However, blood pressure at discharge was still significantly less likely to be controlled in patients with HF-preserved EF and HF-borderline EF compared with HF-reduced EF (adjusted OR, 0.53 for HF-borderline EF versus HF-reduced EF and 0.44 for HF-preserved EF versus HF-reduced EF; P�0.001 for each). Patients with HF-preserved EF were also EF indicates ejection fraction; ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Shown are vital signs at discharge with unadjusted rates of medication use at discharge, quality measures, outcomes, and discharge status across EF category.
still more likely to be discharged to a skilled nursing facility (adjusted OR, 1.67 versus HF-reduced EF; P�0.001) and less likely to be discharged home (adjusted OR, 0.67 versus HF-reduced EF; P�0.001). For the end point of in-hospital mortality, testing for interaction between EF and age was significant (P�0.03). Compared with patients with HFreduced EF, those with HF-preserved EF had significantly lower in-hospital mortality across age groups (P�0.001 for all comparisons). This gap in in-hospital mortality rates attenuated with increasing age.
In analyses of temporal trends, the proportion of patients hospitalized with HF-preserved EF increased from 33% in 2005 to 39% in 2010 (see Figure 1 ) with a concomitant decrease in the proportion with HF-reduced EF from 52% to 47% and stable rates of HF-borderline EF at �15% (P�0.0001 for overall trend, unadjusted). Rates of angioten- EF indicates ejection fraction; OR, odds ratio; CI, confidence interval; and ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. Multivariable analysis of overall quality measures and outcomes. The group with EF �40% (heart failure-reduced EF) was used as the reference group for all comparisons. Adjusted for age, sex, race, insurance, history of atrial fibrillation, atrial flutter, chronic obstructive pulmonary disease or asthma, diabetes mellitus, hyperlipidemia, hypertension, peripheral vascular disease, prior myocardial infarction, cerebrovascular accident/transient ischemic attack, prior heart failure, anemia, renal insufficiency, smoking, ischemic history, hospital size, hospital type, and region.
*Excludes patients transferred to other acute care facilities. †Testing for interaction between EF and age was significant (P�0.03) for the end point of in-hospital mortality. Table 4 ). Temporal trends in renal function are shown in Table III in the online-only Data Supplement. For each year during the study period, quality-of-care measures applicable across groups of EF showed a trend toward improvement. In univariate analyses, patients in all EF groups were more likely to receive discharge instructions, smoking cessation counseling, anticoagulation for AF, and lipid-lowering therapy and to achieve goal blood pressure at discharge over the 5 years (see Figure 2) . These improvements were persistently significant in the multivariable generalized estimating equation model across EF groups, with the exception of blood pressure control (see Table 4 ). In multivariable analysis, there was no significant improvement in the achievement of goal blood pressure goal at discharge in any EF group over the study period (adjusted OR, 1.0 per year for each group; P�0.40, P�0.64, and P�0.41 for HFreduced EF, HF-borderline EF, and HF-preserved EF, respectively).
Unadjusted rates of in-hospital mortality for patients with HF-preserved EF decreased from 3.32% in 2005 to 2.35% in 2010 (P�0.015) but were stable for patients with HFreduced EF (3.03%-2.83%; P�0.522) and HF-borderline EF (2.69%-2.88%; P�0.320; see Figure 3 ). There were no clinically significant changes in discharge status (home versus skilled nursing facility) over the study period for any EF group in both unadjusted and adjusted analyses. However, there was a significant improvement in risk-adjusted in- 
Discussion
In this cohort of �110 000 hospitalizations for heart failure, HF-preserved EF accounted for more than one third of all hospitalizations, and these patients represented an increasing share of heart failure hospitalizations over the study period. There was significant improvement in several quality measures in patients with HF-preserved EF during the study period except for blood pressure control at discharge. After risk adjustment, patients with HF-preserved EF had intermediate rates of in-hospital mortality and were the only group observed to have a decline in in-hospital mortality rates during the study period.
The rise in the prevalence of HF-preserved EF relative to HF-reduced EF emphasizes the growing need for effective, evidence-based therapies in this population. Although such an increase may represent heightened physician recognition of HF-preserved EF as a disease process, other studies have demonstrated similar rates of HF-preserved EF among patients hospitalized for heart failure. 3, 4 Among those hospitalized with heart failure, HF-preserved EF is rising rapidly and could easily eclipse HF-reduced EF as the predominant disease manifestation over the next decade. Furthermore, care of these patients is likely to become more complicated. Patients with HF-preserved EF in our study were significantly older, more likely to be female, and more likely to have hypertension, renal disease, AF, and pulmonary disease than those with HF-reduced EF or HF-borderline EF. These characteristics are consistent with populations reported in both the Acute Decompensated Heart Failure National Registry (ADHERE) and Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF) registries, 3, 4 as well as older, regional studies. 13, 14, 16 As observed in this study, there were significant differences in in-hospital therapies across EF categories. Patients with HF-preserved EF were less likely to receive therapies broadly recommended to reduce cardiovascular risk (eg, optimal blood pressure control) and less likely to undergo in-hospital procedures. Although increased comorbidities in patients with HF-preserved EF and the absence of specific recommendations targeting this population certainly can account for some of these disparities, it is clear that more clinical trials and evidence are needed to direct the management of HF-preserved EF. Current therapies proven to be beneficial in HF-reduced EF either have failed to improve outcomes in HF-preserved EF (angiotensin receptor blockers 8, 9 ) or have yet to be rigorously studied (�-blockers). The ongoing Trial for Heart Failure Patients With Preserved Systolic Function (TOPCAT) study will likely provide valuable data on the utility of aldosterone antagonism in this population. 17 During the study period, we observed a decrease in the prescription of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers at discharge and an increase in �-blocker use across EF groups. This may be partly the result of the failure of contemporary trials to demonstrate a clinical advantage for the use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker in HF-preserved EF. 8, 9 However, these findings may also represent an increasing prevalence of contraindications and comorbidities precluding the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ie, renal dysfunction), particularly within the growing HF-preserved EF population (in which we observed a higher rate of renal disease). Because quality measures related to such medications are currently applicable only to patients with LV systolic dysfunction, such contraindications and intolerances were not applied in the present study. In the overall cohort, there were also improvements in broadly applicable cardiovascular therapies such as blood pressure control, anticoagulation for AF, lipid-lowering therapy, and smoking cessation, which have been demonstrated to benefit patients with cardiovascular disease regardless of EF.
Discrepancies in the implementation of broadly applicable therapies also may be due to treatment biases in which physicians perceive patients with HF-preserved EF to be less sick than their counterparts with low EF. This is supported by the fact that patients with HF-preserved EF were less likely to receive heart failure discharge instructions, even after adjustment in multivariable analysis. Previous descriptions of "diastolic" heart failure asserted that mortality was lower in this population. 18 Yet, this assumption may be incorrect. Our data demonstrate relatively small differences in absolute in-hospital mortality rates across EF strata (2.5% for HFpreserved EF, 2.3% for HF-borderline EF, and 2.7% for HF-reduced EF). Furthermore, patients with HF-preserved EF in our cohort had a significantly longer hospital stay and were much more likely to require skilled nursing care, even after multivariable adjustment for confounders. These observations confirm data from OPTIMIZE-HF 3 and from a study by Senni et al 19 that reviewed several epidemiological studies of heart failure outcomes. Their data suggest that outcomes in patients with a clinical diagnosis of heart failure are not substantially different across the spectrum of EF. However, the overall absolute rate of in-hospital mortality for patients with HF-preserved EF in the present study (2.5%) differed from those previously reported in the OPTIMIZE-HF (2.9%) and ADHERE (2.8%) cohorts. 3, 4 Several explanations for this discrepancy are likely. One may be that the ADHERE and OPTIMIZE-HF studies involved earlier time frames than the present study. In-hospital mortality from the present study in 2006 matches that of the OPTIMIZE-HF cohort published that same year (2.8%). There were also differences in the portion of patients in whom EF was quantified. In the OPTIMIZE-HF population, patients without quantitative EF measurements were included in the HF-preserved EF group (if a qualitative EF assessment did not show moderate/severe LV dysfunction). 3 Other differences in the patient populations and their treatment also may account for these modest differences in inhospital mortality.
Despite these findings, patients with HF-preserved EF in our study were the only group in whom improvement in short-term mortality was observed over the 5-year study. A single source for such a decline is difficult to identify. One possibility is that more patients were receiving a HFpreserved EF diagnosis over time and that these patients have less severe disease and were at lower risk for in-hospital mortality. Significant differences in BNP levels or in the proportion with BNP �100 pg/dL were not observed, however. Another possibility is that patients with HF-preserved EF represent �1 disease process, which could not be adjusted for in multivariable analysis. 20 A further possibility is advancements in the care of these patients. However, this is less likely given that the several trials of therapies in HFpreserved EF during this period did not precipitate dramatic paradigm shifts in care. 8, 9, 11, 21 A decline in the use of agents found to increase mortality in patients hospitalized for heart failure is possible. In a similar observational study run during the period immediately preceding ours, investigators in the ADHERE registry highlighted the declining use of inotropes in hospitalized patients with heart failure. They cite this as 1 potential contributor to a drop in mortality over the period of that study. 22 Additional data from ADHERE, which included patients with both HF-preserved EF and HF-reduced EF, emphasized the adverse effect of inotropes across all populations of heart failure. 23 The improvements in broad cardiovascular care that we observed spanned the spectrum of EF without a similar effect on mortality throughout. This raises the possibility of a more profound treatment effect of routine cardiovascular prevention therapies in patients with HFpreserved EF than in those with borderline or reduced EF. However, current data supporting this hypothesis are lacking.
Limitations
The data presented here are derived from an observational registry in which participation is voluntary and targeted at sites motivated to improve quality. They are thus subject to the inherent limitations of such methods, including biases related to patient population, patient selection and reporting, and the self-selection of sites that agree to participate in GWTG-HF. Therefore, this patient population may not be representative of the United States as a whole. Furthermore, given the large sample size, many comparisons may result in statistically significant results of questionable clinical significance. The diagnosis of heart failure itself also may have been confounded in patients with HF-preserved EF. Although standard criteria have been proposed for the diagnosis of HF-preserved EF, they frequently rely on the assessment of diastolic dysfunction, which can be difficult to demonstrate noninvasively (and was not available in the present study). 1, 24 The diagnosis of HF-preserved EF in our cohort depended on the assessment of EF combined with the clinical presentation of heart failure (signs and/or symptoms of volume overload). However, the proportion of patients with BNP levels �100 pg/mL in each stratum of EF was �5%, comparable to prior reports of the false-negative rate for this test in patients with clinically diagnosed heart failure. 3, 25 Additionally, we must acknowledge the limitations inherent in using EF as a global assessment of myocardial health. Although it can provide an important visual assessment of LV contraction, EF captures only a fraction of data on hemodynamics, loading conditions, and diastolic function. Furthermore, EF in the present study could have been measured by a variety of different modalities (echocardiography, cardiac magnetic resonance, angiography, etc). Thus, there may be some heterogeneity in the study population owing both to diagnostic variability and to limitations in the assessment of EF. Finally, we cannot exclude residual measured and unmeasured confounding factors that may account for different outcomes among these groups. Although our model adjusted for such discrepancies, it is impossible to correct for such an effect entirely.
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